Semaglutide is a GLP-1 receptor agonist peptide or injectible indicated for the treatment of Type-2 Diabetes
Mellitus and obesity. The molecule has demonstrated strong clinical ef cacy in glycemic control,
cardiovascular risk reduction, and sustained weight management. With expanding global demand
and growing opportunities in the generic segment, semaglutide represents a key strategic product
for peptide or injectible-based PFS manufacturing.